RSM, the world 6th largest consulting and auditing network, carried out the financial and tax due diligence for Voisin Consulting Life Sciences (VCLS), a global HealthTech solution provider offering end-to-end solutions, during the acquisition of MedEngine, a leading medical science agency in the Nordics. 

RSM partners in Transaction Advisory Services, Eric Fougedoire and Oliver Smyth, supervised a Franco-Scandinavian team based in Paris and Oslo to support VCLS in this transaction.

This transaction confirms the Corporate Finance pole's role as advisor to life sciences regulatory advisors on their strategic acquisitions in Europe.


Voisin Consulting Life Sciences (VCLS), a prominent global HealthTech solution provider offering end-to-end solutions from preclinical to post-launch, announced today the acquisition of MedEngine, a leading medical science agency in the Nordics. This results in the creation of one of the world’s most comprehensive scientific hubs for innovative therapies, serving a broad range of developers and investors in life sciences.

The acquisition unites two companies with highly complementary service offerings, both sharing a commitment to scientific excellence, individual empowerment, and a dedication to enhancing patient outcomes through continuous innovation. VCLS’s services span from the pre-clinical development stage to post-approval regulatory services. Synergistically, MedEngine’s expertise begins at real-world evidence generation and market access, extending across all post-marketing medical and commercial phases.


«The acquisition strengthens VCLS’s digital capabilities and facilitates versatile use of RWD, for example, to support market access efforts and the creation of virtual control arms in clinical studies »,  says Dr. Emmanuelle Voisin, Founder and CEO of VCLS.


This strategic merger positions the VCLS group as one of the most comprehensive platforms, providing science-driven interdisciplinary solutions in science and technology, regulatory science, market access, real-world evidence, and commercialization services. These services enable innovators in Biotech, Pharma, MedTech and digital health to thrive in their competitive markets.


« “We have strategically built MedEngine as the Nordic leader in evidence generation, market access, and scientific content creation — and we are excited about this new chapter in our journey. We believe that this partnership is a perfect strategic fit, ensuring a promising future for our talented team as they become part of a company that shares our values and vision for innovation and growth», says Tero Ylisaukko-oja, Founder and CEO of MedEngine.


MedEngine will retain its brand identity, continuing to oversee and develop its Market Access, Medical Data Science, and Scientific Content Solutions business segments globally. The transaction will open unique opportunities for existing and future clients through the expanded range of services offered by the VCLS group.


RSM Team

The RSM team involved was made up of :

  • RSM in France : Eric Fougedoire
  • RSM in Norway : Oliver Smyth & Simen Solberg